T. Rowe Price Associates’s Niagen Bioscience, Inc. Common Stock NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $789K | Buy |
54,745
+3,536
| +7% | +$51K | ﹤0.01% | 2088 |
|
|
2025
Q1 | $354K | Sell |
51,209
-6,095
| -11% | -$42.1K | ﹤0.01% | 2393 |
|
|
2024
Q4 | $304K | Buy |
57,304
+2,196
| +4% | +$11.7K | ﹤0.01% | 2496 |
|
|
2024
Q3 | $202K | Hold |
55,108
| – | – | ﹤0.01% | 2648 |
|
|
2024
Q2 | $151K | Buy |
55,108
+15,808
| +40% | +$43.3K | ﹤0.01% | 2666 |
|
|
2024
Q1 | $137K | Hold |
39,300
| – | – | ﹤0.01% | 2717 |
|
|
2023
Q4 | $57K | Hold |
39,300
| – | – | ﹤0.01% | 2790 |
|
|
2023
Q3 | $58K | Hold |
39,300
| – | – | ﹤0.01% | 2757 |
|
|
2023
Q2 | $62K | Hold |
39,300
| – | – | ﹤0.01% | 2771 |
|
|
2023
Q1 | $61K | Hold |
39,300
| – | – | ﹤0.01% | 2763 |
|
|
2022
Q4 | $66K | Buy |
39,300
+16,800
| +75% | +$28.2K | ﹤0.01% | 2777 |
|
|
2022
Q3 | $28K | Hold |
22,500
| – | – | ﹤0.01% | 2891 |
|
|
2022
Q2 | $38K | Sell |
22,500
-30,772
| -58% | -$52K | ﹤0.01% | 2883 |
|
|
2022
Q1 | $131K | Buy |
53,272
+17,600
| +49% | +$43.3K | ﹤0.01% | 2793 |
|
|
2021
Q4 | $133K | Sell |
35,672
-1,000
| -3% | -$3.73K | ﹤0.01% | 2826 |
|
|
2021
Q3 | $230K | Buy |
36,672
+11,281
| +44% | +$70.8K | ﹤0.01% | 2668 |
|
|
2021
Q2 | $250K | Buy |
25,391
+7,113
| +39% | +$70K | ﹤0.01% | 2638 |
|
|
2021
Q1 | $171K | Sell |
18,278
-9,916
| -35% | -$92.8K | ﹤0.01% | 2718 |
|
|
2020
Q4 | $135K | Buy |
28,194
+11,500
| +69% | +$55.1K | ﹤0.01% | 2601 |
|
|
2020
Q3 | $67K | Buy |
+16,694
| New | +$67K | ﹤0.01% | 2529 |
|